Akebia Therapeutics Inc
Akebia Therapeutics Inc (AKBA) Option Chain
Read more
Tracking the AKBA option chain helps you see every strike and expiry on Akebia Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AKBA options activity at a glance. Use our scanner to monitor the AKBA option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AKBA stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AKBA options are being actively traded, and where they are not.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| Loading option chain… | |||||||||||||||
As of Nov 5, 2026
Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank92.86% High
- Market cap (M$)118
- 52 weeks high-79.62%
- 52 weeks low-20.37%
- Analyst recommendationStrong Buy
1.33 - Target price$3.75
876.83% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-0.11
- EPS growth next 5 years—
As of Nov 5, 2026